| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6197819 | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Dec, 2018
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE41920 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(5 years ago) | |
|
US6197819 (Pediatric) | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Jun, 2019
(4 years ago) | |
|
USRE41920 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(4 years ago) | |
| US10022447 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(2 years from now) | |
| US9144559 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(2 years from now) | |
| US8945620 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(2 years from now) | |
|
US10022447 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(3 years from now) | |
|
US8945620 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(3 years from now) | |
|
US9144559 (Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(3 years from now) | |
Lyrica Cr is owned by Upjohn.
Lyrica Cr contains Pregabalin.
Lyrica Cr has a total of 10 drug patents out of which 4 drug patents have expired.
Expired drug patents of Lyrica Cr are:
- USRE41920
- US6197819*PED
- USRE41920*PED
- US6197819
Lyrica Cr was authorised for market use on 11 October, 2017.
Lyrica Cr is available in tablet, extended release;oral dosage forms.
Lyrica Cr can be used as treatment of neuropathic pain associated with diabetic peripheral neuropathy.
The generics of Lyrica Cr are possible to be released after 02 May, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 11, 2020 |
| Pediatric Exclusivity(PED) | Apr 11, 2021 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 11 October, 2017
Treatment: Treatment of neuropathic pain associated with diabetic peripheral neuropathy
Dosage: TABLET, EXTENDED RELEASE;ORAL
LYRICA CR family patents
